News

 

It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

Corporate news

2021
Evotec publishes DDup 11 – AI-driven antibody discovery at Evotec
Hamburg, Germany, September 15, 2021

The 11th edition is dedicated to our exciting new capabilities in the biologics lane of Evotec’s “Multi-modality Autobahn.” 

Evotec partner Bayer: Phase IIb trial shows eliapixant significantly decreases cough frequency in patients with refractory chronic cough
Berlin, Germany, September 6, 2021

Evotec partner Bayer today reported more detailed results from PAGANINI, the Phase IIb dose-finding study evaluating the efficacy and safety of eliapixant in patients with refractory chronic cough (“RCC”). Eliapixant (BAY1817080) is an investigational orally administered, potent and selective P2X3 receptor antagonist derived from a former multi-target research collaboration between Bayer and Evotec. 

Evotec announces Bristol Myers Squibb opt-in of EVT8683 as the first programme from iPSC-based neurodegeneration collaboration
Hamburg, Germany, September 2, 2021

Evotec SE announced today that Bristol Myers Squibb Company has exercised its option to enter into an exclusive global license for EVT8683 which comes from a broader neurodegeneration collaboration. EVT8683 is a small molecule targeting a key cellular stress response that holds great promise in various neurodegenerative indications and is ready to enter clinical development. The programme originated from a phenotypic screening approach based on Evotec’s leading iPSC platform and reached IND filing within only 5 years. Under an option agreement with Celgene (which is now a Bristol Myers Squibb company), Bristol Myers Squibb has rights to additional programmes in neurodegenerative diseases.

Evotec partner Kazia Therapeutics announces full regulatory approval for Phase I study of EVT801
Sydney, Australia, September 2, 2021

Evotec partner Kazia Therapeutics Limited today announced that the planned phase I study for EVT801 has received full approval from L’Agence Nationale de Sécurité du Médicament et des Produits de Santé (“ANSM”), the French regulatory agency. The study is expected to open to recruitment by the end of CY2021.

Evotec and Secarna Pharmaceuticals expand strategic partnership in the field of antisense drug discovery
Munich/Martinsried and Hamburg, Germany, September 2, 2021

Evotec SE and Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide ("ASO") therapies to address challenging or previously undruggable targets via its LNAplus™ platform, have expanded their strategic partnership in the field of ASO-based therapeutics.

Evotec SE reports first half-year 2021 results and corporate updates
Hamburg, Germany, August 11, 2021

Evotec SE today announced its financial results for the first half-year of 2021: Strong overall performance in the first half of 2021 gaining speed; rapid capacity build-up to foster undisputed growth and future margin expansion; registration statement for proposed offering of American Depositary Shares submitted; guidance for full-year 2021 confirmed; webcast and conference call today at 2.00 pm CEST

Just - Evotec Biologics opens J.POD® 1 US in Redmond, Washington
Hamburg, Germany, August 11, 2021

Evotec SE today announced the opening of the company’s late-stage clinical and commercial biologics cGMP manufacturing facility (J.POD® 1 US) in Redmond, Washington. The innovative cGMP biomanufacturing facility is the final step in Just – Evotec Biologics’ J.DESIGN platform that integrates data analytics and machine learning through all activities involved with the discovery, development, and manufacture of biologics. This includes design of discovery libraries (J.DISCOVERY™), molecules (J.MD™), processes (JP3®) and the manufacturing facility, J.POD®.

Evotec spin-off Topas Therapeutics extends Series B, raising total of € 40 m (~$ 48 m) in this round
Hamburg, Germany, July 29, 2021

Evotec spin-off company Topas Therapeutics GmbH ("Topas"), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, today announced that the Company has successfully extended its Series B round with an additional € 18 m (~$ 22 m) raised, bringing the total for this financing to € 40 m. All of Topas’ existing investors participated in the extension.

Evotec creates long-term growth opportunities by initiating “Campus Levi-Montalcini” in Verona
Hamburg, Germany, July 1, 2021

Evotec SE today announced that Evotec has added significant opportunities for further, long-term growth by acquiring the Verona site from GlaxoSmithKline SpA. During a site meeting, the employees also decided on a new name for their campus. In commemoration of Italian Nobel laureate Rita Levi-Montalcini, the Verona site will be named “Campus Levi-Montalcini” going forward.

Evotec launches “PRROTECT”, a pre-competitive initiative to be better prepared for future pandemics
Hamburg, Germany, June 15, 2021

Evotec SE announced today that the Company has launched an initiative for pandemic preparedness (“PRROTECT”). PRROTECT leverages a comprehensive set of novel projects and technologies to be better prepared for and respond faster to viral pandemics of the future.

Evotec SE Virtual Annual General Meeting 2021 approves all proposed agenda items
Hamburg, Germany, June 15, 2021

Evotec SE today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s virtual Annual General Meeting 2021 with the required majority. Due to the COVID-19 pandemic, this year’s Annual General Meeting again was held as a purely virtual event. 

Evotec partners with CEBINA to launch Danube Labs, a partnership to develop cutting edge biotechnology projects sourced from Central and Eastern European Universities and Research Institutions
Vienna, Austria, June 14, 2021

CEBINA GmbH today announces the launch of Danube Labs, a partnership with Evotec SE to fast-track early-stage academic research to drug discovery and development. The joint project, financed by a dedicated group of private investors, will identify, and develop academic projects into mature therapeutic product development opportunities, primed for biotech company formation or partnering.

Autobahn Labs incubator announces partnership with Cold Spring Harbor Laboratory to advance novel science to the clinic
Palo Alto, CA, USA, June 7, 2021

Autobahn Labs, an early-stage drug discovery incubator, today announced a new strategic venture collaboration with Cold Spring Harbor Laboratory (CSHL). Together with Autobahn Labs, CSHL will identify promising research programs with therapeutic potential and partner to form promising new drug discovery companies.

Evotec SE reports results for the first quarter 2021 and provides corporate update
Hamburg, Germany, May 11, 2021

Evotec SE today announced the financial results and corporate updates for the first quarter 2021. Group revenues from contracts with customers increased by 11% to € 133.1 m (Q1 2020: € 119.4 m); Base business growth of 28%, adjusted for the end of the Sanofi payment (since April 2020) and unfavourable fx effects; EVT Execute revenue growth of 16% (11% adjusted for material recharges) to € 136.9 m (Q1 2020: € 118.2 m), EVT Innovate revenues up 21% (20% adjusted for material recharges) to € 28.2 m (Q1 2020: € 23.3 m)

Evotec launches "beLAB1407" to accelerate translational research from the UK's academic life science ecosystem in collaboration with Bristol Myers Squibb
Hamburg, Germany, May 6, 2021

Evotec SE announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of Evotec’s drug discovery and development platforms and early-stage therapeutic concepts from the Universities of Birmingham, Edinburgh, Nottingham, and Dundee, beLAB1407 offers a unique route to the advancement of first-in-class therapeutics and the creation of spin-out companies.

Evotec and the GCKD study enter into strategic collaboration to build a unique molecular patient database
Hamburg and Erlangen, Germany, May 4, 2021

Evotec SE and the University Hospital Erlangen today announced a partnership regarding molecular analyses of biospecimens from the German Chronic Kidney Disease (“GCKD”) cohort study. Under the agreement, the research team will make use of Evotec’s proprietary EVOpanOmics and EVOpanHunter platforms to facilitate deep molecular profiling of patient samples. The Evotec platforms combine enhanced throughput proteomics, high-throughput transcriptomics and integrated data analysis. 

Evotec SE to announce results for the first quarter 2021 on 11 May 2021
Hamburg, Germany, May 4, 2021

Evotec SE will announce its financial results for the first quarter of 2021 on Tuesday, 11 May 2021. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Bristol Myers Squibb exercises option to extend targeted protein degradation partnership with Evotec
Hamburg, Germany, April 26, 2021

Evotec SE today announced that Bristol Myers Squibb has decided to exercise their option to extend its partnership with Evotec in the field of targeted protein degradation. Evotec and Bristol Myers Squibb (the successor in interest to Celgene) initiated this strategic drug discovery and development partnership in 2018 with the goal to identify first-in-class drug candidates initially focusing on solid tumours.

Evotec invests into Oxford Cell Therapy Company "OxVax"
Hamburg, Germany, April 21, 2021

Evotec SE announced today that the Company has invested into OxVax, a new immuno-oncology company based on research from Oxford University, which enables the development of the next generation of cancer vaccines with the potential to overcome the limitations of the current approaches.

Evotec accelerates access to biologic therapeutics with initiation of manufacturing facility in Toulouse
Hamburg, Germany, April 20, 2021

Evotec SE today announced that the Company has initiated the construction of its J.POD® 2 EU biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® 2 EU, Evotec’s second innovative cGMP biomanufacturing facility, will employ Just – Evotec Biologics’ cutting-edge technology that utilizes small, automated, highly intensified and continuous bioprocessing operations housed inside autonomous cleanrooms.

Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801
Hamburg, Germany, April 19, 2021

Evotec SE announced today that the Company has entered into both a licensing and master service agreement with Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialisation of Evotec’s oncology project EVT801.

Evotec launches “beLAB2122”, translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb
Hamburg, Germany, April 13, 2021

Evotec SE announced today that the Company has launched beLAB2122, a translational $ 20 million BRIDGE in collaboration with Bristol-Myers Squibb Company. beLAB2122 brings together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects.

Evotec and Exscientia announce start of human clinical trials of novel immuno-oncology drug
Hamburg, Germany, April 9, 2021

Evotec SE today announced the most advanced asset arising from their joint venture with Exscientia has entered human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed between Exscientia and Evotec, including application of Exscientia’s next generation 3-D evolutionary AI-design platform, Centaur Chemist®. The drug candidate has potential for best-in-class characteristics, with high selectivity for the target receptor, bringing together potential benefits of reduced systemic side effects as well as minimal brain exposure to avoid potential undesired centrally-mediated side effects.

The Science Pool: Evotec’s New Scientific Content Hub
Hamburg, Germany, March 26, 2021

Knowledge sharing within the scientific community is a key focus for Evotec. Sharing resources will help to collectively advance R&D and accelerate innovation - ultimately leading to new technology and therapies reaching the market faster. 

Evotec SE fiscal year 2020 results: Gaining speed on the "data-driven R&D Autobahn to Cures"
Hamburg, Germany, March 25, 2021

Very strong financial results: 12% increase in Group revenues beating guidance despite pandemic; unique innovation platforms and infrastructure support long-term growth in all modalities; solid balance sheet, strong foundation for next expansion steps

Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance
Hamburg, Germany, March 22, 2021

Evotec SE today announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.

Evotec SE to announce results for fiscal year 2020 on 25 March 2021
Hamburg, Germany, March 18, 2021

Evotec SE will announce its financial results for 2020 on Thursday, 25 March 2021. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

CMO Leadership Awards 2021
Hamburg, Germany, March 18, 2021

Evotec announces that the Company has been selected as a winner of a 2021 CMO Leadership Award in the categories Compatibility (Big Pharma), Expertise (Big Pharma), and Service (Overall, Small Pharma)

G-CON Manufacturing and Just – Evotec Biologics Complete the Installation of Cleanroom PODs® for the First J.POD® Facility in North America
College Station, Texas, and Redmond, Washington, USA, March 16, 2021

Just – Evotec Biologics’ Redmond, Washington site offers true meaning to “Facility of the Future” with flexible and podular manufacturing of clinical and commercial-stage biologics.

Argobio announces its launch with 50 M€ to create and develop pioneering biotech spinouts with the support of Bpifrance, Kurma Partners, Angelini Pharma, Evotec, and the Institut Pasteur
Paris, France, March 2, 2021

Argobio SAS, a newly-created start-up studio dedicated to life sciences, today announced its launch with 50 M€ of committed capital. Argobio was initiated by Kurma Partners, a leading Paris and Munich-based healthcare venture capital firm, and Bpifrance, the French national investment bank. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, internationally renowned center for biomedical research. 

Evotec and Chinook Therapeutics enter into strategic collaboration to discover and develop novel precision medicines for chronic kidney diseases
Hamburg, Germany, March 1, 2021

Evotec SE and Chinook Therapeutics, Inc. today announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases (“CKD”). Based on Evotec’s proprietary comprehensive molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook and Evotec will jointly identify, characterise and validate novel mechanisms and discover and develop precision medicines. 

Evotec and Related Sciences enter integrated drug discovery and development partnership
Hamburg, Germany, February 9, 2021

Evotec SE announced today that the Company has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period.

Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure
Hamburg, Germany, February 4, 2021

Evotec SE today announced that the Company has entered into a multi-year partnership with the Medical Center Hamburg-Eppendorf (“UKE”) for the development of a highly innovative first-in-class cell therapy approach for the treatment of heart failure.

Evotec Statement on COVID-19
Hamburg, Germany, February 1, 2021

Many of you have been asking us about the Coronavirus and its potential impact on Evotec and its affiliates. At Evotec, we are actively managing our operations to maintain business continuity while taking measures to protect the health and wellbeing of our employees, their families and the local communities in which they live and work. We have taken a number of steps to ensure the continued health and safety of our colleagues and prepare our business during this challenging time.

Evotec CSO Cord Dohrmann Appointed to German Council of Science and Humanities
Hamburg, Germany, February 1, 2021

Evotec today announced that Dr Cord Dohrmann has been appointed to the German Council of Science and Humanities (German: “Wissenschaftsrat”) for a term of three years. He is appointed by the Federal President Frank-Walter Steinmeier on the joint recommendation of the German Federal Government and the governments of the German states.

Evotec Starts Clinical Development of Chikungunya Antibody together with NIAID and Leading Academic Research Organisation
Hamburg, Germany, January 28, 2021

Evotec SE today announced that EVT894, a monoclonal antibody to treat and potentially prevent chikungunya virus infections, has entered clinical development. 

Just – Evotec Biologics Expands Contract with the Department of Defense for Manufacturing of Monoclonal Antibodies
Hamburg, Germany, January 27, 2021

Evotec SE today announced that the U.S. Department of Defense (“DOD”) awarded its Seattle, Washington-based subsidiary, Just – Evotec Biologics, Inc., an agreement worth $28.6 million for the production of monoclonal antibodies (“mAbs”) for use in the development of a treatment and/or prophylaxis for COVID-19.

Evotec to attend upcoming investor conferences
Hamburg, Germany, January 7, 2021

Evotec SE announced today that its management will be presenting at and attending the following upcoming conferences in the first quarter of 2021:

Evotec achieves milestone in its neurodegeneration collaboration with Bristol Myers Squibb
Hamburg, Germany, January 5, 2021

Evotec SE announced today that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company (NYSE:BMY) within the companies’ iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb’s decision to add another drug discovery project to the partnership’s portfolio.

 

Ad hoc releases

Please find below Evotec's most recent ad hoc releases according to Article 17 European Market Abuse Regulation (MAR).

 

2021
Evotec SE: Positive Phase IIb data for investigational P2X3 antagonist in patients with refractory chronic cough
Hamburg, Germany, August 3, 2021

Evotec SE announces that the Company has been informed by Bayer about positive Phase IIb results from a clinical trial evaluating the efficacy and safety of the investigational P2X3 receptor antagonist eliapixant (BAY1817080) in patients with refractory chronic cough. The underlying molecule is a P2X3 receptor antagonist in Bayer’s clinical development pipeline originating from a former Evotec/Bayer multi-target research alliance. The primary efficacy outcome was met showing a statistically significant improvement in 24-hour cough counts per hour (average hourly cough frequency based on 24-hour sound recordings) over placebo after 12 weeks of treatment. The data showed a favourable safety and tolerability profile.

Evotec SE Announces Confidential Submission of Draft Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a Proposed Offering of American Depositary Shares
Hamburg, Germany, August 2, 2021

Evotec SE announces that it confidentially submitted a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed offering and sale in the United States of shares of Evotec represented by American Depositary Shares. The Registration Statement has not yet become effective and the final number of ADSs to be offered and their price have not yet been determined.

Chairman of the Supervisory Board of Evotec to resign from office effective as of the end of the Annual General Meeting on 15 June 2021
Hamburg, Germany, April 23, 2021

Evotec SE announces that today the Chairman of the Supervisory Board, Prof. Dr Wolfgang Plischke, has informed the Company of his decision to resign from his office in the Supervisory Board of Evotec SE effective as of the end of the Annual General Meeting on 15 June 2021 due to personal reasons. Prof. Dr Plischke has been serving in the Supervisory Board as Chairman since 2014.

 

 

Contact us

Gabriele Hansen

SVP, Head of Global Corporate Communications & Marketing

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Volker Braun

SVP, Head of Global Investor Relations & ESG

T +49 40 560 81 775 vCard

Hinnerk Rohwedder

Senior Specialist Corporate Communications

T +49 40 560 81 281 F +49 40 560 81 222 vCard

Anja Ben Lekhal

Investor Relations Associate

T +49 40 56081 210 vCard

Anika Meier

Investor Relations Manager

T +49 40 560 839 vCard

Thore Schmidt

Investor Relations & ESG Coordinator

T +49 40 560 81 857 vCard
TOP